Novolimus™ is a metabolite of the drug Sirolimus, a novel mTOR inhibitor macrolytic lactone with anti-proliferative and anti-inflammatory properties developed by Elixir Medical. The macrocyclic lactone drugs represent the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy profile.
Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications:
- Drug-eluting stents
Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, DESyne® BD and the fully resorbable DESolve® and DESolve® Cx scaffolds have resulted in excellent clinical outcomes and sustained safety and effectiveness.
The DESyne BD Novolimus-Eluting Coronary Stent System represented a significant advancement in biodegradable coating technology, eliminating the need for a primer coating and achieving a bare metal surface within six to nine months, while providing excellent DES results.
The DESolve Scaffold System was a state-of-the-art novolimus-eluting bioresorbable coronary scaffold system that represented the next generation in scaffold technology. Unlike conventional metal stents, DESolve degraded in about one year, leaving behind a thin neointimal lining and well-maintained lumen – similar to a de novo vessel. DESolve CX Plus was an advancement of the DESolve Scaffold System, designed to maintain the platform’s unique polymer characteristics while improving deliverability.7
*These products are not approved by the United States Food and Drug Administration (FDA).